Tweet
I plot the same set of data with heatmap and heatmap.2 respectively, and got distinctly different profiles. Anybody could explain this? I know heatmap.2 has extra functions, such as color key; but it looks that its imaging algorithm might also be quite different from heatmap. Is it true? Thanks.
-
-
I noticed the same thing some time ago...
heatmap does not use the same colorkey for every row by default. Instead it performs some weird scaling...
This essentially means that the rows are NOT comparable by means of colour, since the scaling is performed independently for every row.
you can try this very easily with the following commands:
x = c(1:10)
a = cbind(x,x,x,x)
a[1,2] = 100
a[1,3] = 1000
heatmap(a)
Here's what the help says:
"By default (scale = "row") the rows are scaled to have mean zero and standard deviation one. There is some empirical evidence from genomic plotting that this is useful. "
set scale = "none" and your results will be comparable.
heatmap(a,scale="none")
heatmap.2(a,trace="none")
Best regards,
René -
Thanks for help
Comment
-
Proteomics platforms are evolving rapidly, with advances in mass spectrometry and affinity-based approaches expanding what researchers can detect and at what scale. As the field moves toward deeper proteome coverage and clinical applications, scientists face an increasingly complex landscape of tools. This article will explore how researchers are navigating these choices to find the right platform for their work.
The systematic characterization of the human proteome has...07-20-2026, 11:48 AM -
Genomics studies in neuroscience face a special challenge due to the brain’s complexity and scarcity of samples. Mapping changes in cell type and state using conventional next-generation sequencing methods remains challenging. Advances in technologies like single-cell sequencing, spatial transcriptomics, and long-read sequencing have opened the door to deeper studies of the brain and diseases like Alzheimer’s, amyotrophic lateral sclerosis (ALS), and schizophrenia.
...07-09-2026, 11:10 AM -
Cancer survival rates have significantly increased in the last few decades in the United States, reaching a combined 70% 5-year survival rate by 2021. Behind this number, there are years of research to find new therapies, drug targets, and early detection methods. But there is one core challenge that keeps slowing down these advances, and it’s about drug resistance.
There is no single reason why many patients don’t respond to treatment as expected. Cancer is...07-08-2026, 05:17 AM
Comment